CANDEL THERAPEUTICS, INC. Cash and Restricted Cash
CANDEL THERAPEUTICS, INC. (CADL) had Cash and Restricted Cash of $201.98 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $201.98M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $195.25M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $120.15M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $87.23M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $201.98M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $195.25M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $120.15M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $87.23M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $100.95M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $92.43M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $102.92M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $16.82M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $21.72M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $25.98M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $35.68M 10-K · filed 2026-03-12 |
| 2023-09-30 | $43.25M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $52.16M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $59.52M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $70.32M 10-K · filed 2025-03-13 |
| 2022-09-30 | $77.45M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $87.05M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $94.76M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $83.07M 10-K · filed 2024-03-28 |
| 2021-09-30 | $88.81M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $24.74M 10-Q · filed 2022-08-05 |
| 2021-03-31 | $29.57M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $35.32M 10-K · filed 2023-03-30 |
| 2020-09-30 | $18.52M 10-Q · filed 2021-11-12 |
| 2020-06-30 | $20.76M 10-Q · filed 2021-09-08 |
| 2019-12-31 | $5.45M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |